A Citigroup downgrade to Sell lands just as short sellers accelerate their exit from MRNA, creating an unusual split signal: one major bank is turning bearish on a stock that the shorts who know it best are quietly leaving behind.
Citigroup's Geoff Meacham cut Moderna to Sell this morning, lifting his price target to $80 from $60. At $203.46, that implies 61% downside. It follows a Rothschild downgrade on September 3, also to Sell, with a target of $81.
Neither analyst is wrong to flag the valuation gap. The consensus price target sits at $119.56, less than 60% of the current price. JP Morgan holds an Underweight with an $77 target. Morgan Stanley is at Equal-Weight, target $89. The stock's trailing P/E is deeply negative, and price-to-book has moved from roughly 11.8 to 17.6 over the past month as the share price ran 47%.
Yet Argus Research upgraded to Buy on August 28 with a $180 target. UBS raised its target to $150 on August 20. The analyst community is not moving in one direction. It is fracturing, and the Citigroup note is the loudest bearish voice so far at this price level.
The disagreement with the short book is the detail worth watching. Short interest has fallen 17% in one week and 37% over the past month. From a peak near 51 million shares in late August, positions have been cut to approximately 30.3 million, or 7.8% of the free float. The ESMO oncology data in late September accelerated the covering.
Borrow availability stands at 807%, meaning roughly eight shares remain available to lend for every one currently out on loan. Cost to borrow is 0.42%, close to a generic rate. Short sellers who want to rebuild positions face no friction doing so. Those still short face none exiting either. The borrow market is wide open in both directions.
The ORTEX short score has moved from 51.4 on September 18 to 45.7 on September 28, consistent with a short book that is retreating rather than pressing.
The put/call ratio on September 28 hit 1.29, described in the pulse as 2.33 standard deviations above its 20-day average. By September 29 it had eased back to 1.13, close to the 20-day mean of 1.11. The spike looks like a one-session hedge or a specific options strategy rather than a sustained defensive shift. August saw the PCR running near its 52-week high of 1.51 for several consecutive weeks. The current level is not in that territory.
FMR added 6.1 million shares in its most recent report, lifting its stake to 12.96% of shares outstanding. T. Rowe Price added 4.85 million shares, as reported on September 1. Capital Research and Management added 3.6 million. The institutional buying that accompanied the rally has been substantial.
Insider activity is all pre-arranged. President Stephen Hoge sold approximately $11.7 million in shares on September 14 and 15 under a 10b5-1 plan. CFO James Mock sold around $4.7 million on September 10, also on a plan. Planned sales carry less signal than discretionary ones, but the net insider figure is negative: roughly $49 million sold over the past 90 days.
What to watch: Whether the Citigroup note triggers fresh short positioning, or whether the looseness of the borrow market and the momentum of the past month keeps covering as the dominant trade heading into the November 5 earnings date.
See the live data behind this article on ORTEX.
Open MRNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
